Low-Income Countries And Repurposed Drugs

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15260%2F15%3A33155938" target="_blank" >RIV/61989592:15260/15:33155938 - isvavai.cz</a>
Result on the web
<a href="http://content.healthaffairs.org/content/34/11/2004.2.long" target="_blank" >http://content.healthaffairs.org/content/34/11/2004.2.long</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1377/hlthaff.2015.1223" target="_blank" >10.1377/hlthaff.2015.1223</a>

Result language
angličtina
Original language name
Low-Income Countries And Repurposed Drugs
Original language description
According to the surprising study by Aaron Kesselheim and coauthors (Feb 2015), nine of twenty-six (35 percent) transformative drugs approved by US Food and Drug Administration between 1984 and 2009 were repurposed from products developed for other indications. Drug repurposing, especially of old drugs not under patent protection, seems to be a very attractive approach to drug development for cancer patients in lowincome countries, since patented chemotherapy is very expensive and not transformative interms of curingmetastatic cancers. By investing in efforts to find positive side effects of inexpensive old drugs, low-income countries could make really transformative drugs available for a majority of their citizens.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FQ - Public health system, social medicine
OECD FORD branch
—

Project
<a href="/en/project/GA15-19968S" target="_blank" >GA15-19968S: Spirituality and Health among Adolescents and Adults in the Czech Republic</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)